| Literature DB >> 33717129 |
Javier Sanchez-Solares1, Luis Sanchez2, Carmela Pablo-Torres1, Celso Diaz-Fernandez3, Poul Sørensen4,5, Domingo Barber1,6, Cristina Gomez-Casado1,6.
Abstract
Celiac disease (CD) is a chronic autoimmune disease characterized by an immune-triggered enteropathy upon gluten intake. The only current treatment available is lifelong Gluten Free Diet (GFD). Several extraintestinal manifestations have been described in CD, some affecting the oral mucosa. Thus, we hypothesized that oral mucosa could potentially be a target for novel biomarkers and an administration route for CD treatment. Six de novo diagnosed and seven CD patients under GFD for at least 1 year were recruited. Non-celiac subjects (n = 8) were recruited as control group. Two biopsies of the cheek lining were taken from each subject for mRNA analysis and immunohistochemical characterization. We observed a significant decrease in the expression of epithelial junction proteins in all CD patients, indicating that oral mucosa barrier integrity is compromised. FoxP3+ population was greatly increased in CD patients, suggesting that Tregs are recruited to the damaged mucosa, even after avoidance of gluten. Amphiregulin mRNA levels from Peripheral Blood Mononuclear Cells (PBMCs) and epithelial damage in the oral mucosa correlated with Treg infiltration in all the experimental groups, suggesting that recruited Tregs might display a "repair" phenotype. Based on these results, we propose that oral mucosa is altered in CD and, as such, might have diagnostic potential. Furthermore, due to its tolerogenic nature, it could be an important target for oral immunotherapy.Entities:
Keywords: autoimmune disease; celiac disease; immune mediated disorders; immunotherapy; oral mucosa; regulatory T cells; remodeling; tolerance induction
Year: 2021 PMID: 33717129 PMCID: PMC7947325 DOI: 10.3389/fimmu.2021.623805
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561